{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T03:00:01Z","timestamp":1777950001472,"version":"3.51.4"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Microbiol."],"abstract":"<jats:p>The global rise of multidrug-resistant bacteria necessitates the development of new antimicrobials and faster diagnostic tools. Conventional antimicrobial susceptibility testing is slow, relying on culture-based methods that delay effective treatment, often with fatal consequences in severe infections. In this study, we evaluate flow cytometry as a rapid, culture-minimal method to assess bacterial responses to six antimicrobials: ceftazidime-avibactam, meropenem-vaborbactam, cefiderocol, doxycycline, omadacycline, and lefamulin. Across 165 evaluable antibiotic-isolate combinations, essential agreement between flow cytometry and broth microdilution minimum inhibitory concentrations was 90.71%. Assessable categorical agreement, determined using the European Committee on Antimicrobial Susceptibility Testing and Clinical and Laboratory Standards Institute breakpoints, was 92.59% for doxycycline, 91.67% for omadacycline, and 100% for meropenem-vaborbactam. Cefiderocol exposure was associated with substantial cell elongation, demonstrating cellular-level antimicrobial effects observed using confocal microscopy and imaging flow cytometry. These findings demonstrate the potential of flow cytometry for novel antimicrobial evaluation, offering rapid insights into drug efficacy with potential to improve clinical outcomes in patients.<\/jats:p>","DOI":"10.3389\/fmicb.2026.1817087","type":"journal-article","created":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T05:31:42Z","timestamp":1777872702000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Flow cytometry enables rapid evaluation of novel, new and niche antimicrobial agents"],"prefix":"10.3389","volume":"17","author":[{"given":"Emily","family":"Salisbury","sequence":"first","affiliation":[{"name":"School of Medicine, The University of Western Australia","place":["Crawley, WA, Australia"]},{"name":"Harry Perkins Institute of Medical Research","place":["Nedlands, WA, Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kieran","family":"Mulroney","sequence":"additional","affiliation":[{"name":"School of Medicine, The University of Western Australia","place":["Crawley, WA, Australia"]},{"name":"Harry Perkins Institute of Medical Research","place":["Nedlands, WA, Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malgorzata K.","family":"Kopczyk","sequence":"additional","affiliation":[{"name":"School of Medicine, The University of Western Australia","place":["Crawley, WA, Australia"]},{"name":"Harry Perkins Institute of Medical Research","place":["Nedlands, WA, Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teagan","family":"Paton","sequence":"additional","affiliation":[{"name":"School of Medicine, The University of Western Australia","place":["Crawley, WA, Australia"]},{"name":"Harry Perkins Institute of Medical Research","place":["Nedlands, WA, Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine F.","family":"Carson","sequence":"additional","affiliation":[{"name":"School of Medicine, The University of Western Australia","place":["Crawley, WA, Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wai Shaun","family":"Ho","sequence":"additional","affiliation":[{"name":"School of Medicine, The University of Western Australia","place":["Crawley, WA, Australia"]},{"name":"Harry Perkins Institute of Medical Research","place":["Nedlands, WA, Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aron","family":"Chakera","sequence":"additional","affiliation":[{"name":"School of Medicine, The University of Western Australia","place":["Crawley, WA, Australia"]},{"name":"Harry Perkins Institute of Medical Research","place":["Nedlands, WA, Australia"]},{"name":"Department of Renal Medicine, Sir Charles Gairdner Hospital","place":["Nedlands, WA, Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1007\/s40495-022-00297-6","article-title":"Lefamulin: A new hope in the field of community-acquired bacterial pneumonia.","volume":"8","author":"Adhikary","year":"2022","journal-title":"Curr. Pharmacol. Rep."},{"key":"B2","unstructured":"American Type Culture Collection (ATCC\u00a7) Bacteriology Culture Guide.\n          \n          2022"},{"key":"B3","doi-asserted-by":"publisher","first-page":"778190","DOI":"10.3389\/fmicb.2021.778190","article-title":"Proteomic and transcriptomic analyses indicate reduced biofilm-forming abilities in cefiderocol-resistant Klebsiella pneumoniae.","volume":"12","author":"Bao","year":"2022","journal-title":"Front. Microbiol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1007\/s40121-020-00350-1","article-title":"Microbiology of meropenem-vaborbactam: A novel carbapenem beta-lactamase inhibitor combination for carbapenem-resistant Enterobacterales infections.","volume":"9","author":"Bhowmick","year":"2020","journal-title":"Infect. Dis. Ther."},{"key":"B5","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/s41429-023-00629-8","article-title":"Antibiotics in the clinical pipeline as of December 2022.","volume":"76","author":"Butler","year":"2023","journal-title":"J. Antibiot."},{"key":"B6","volume-title":"Verification of Commercial Microbial Identification and Antimicrobial Susceptibility Testing Systems. CLSI Guideline M52.","year":"2015"},{"key":"B7","volume-title":"Performance Standards for Antimicrobial Susceptibility Testing. CLSI Guideline M100","year":"2023"},{"key":"B8","volume-title":"Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically. CLSI Guideline M07","year":"2024"},{"key":"B9","doi-asserted-by":"publisher","first-page":"eabo7793","DOI":"10.1126\/scitranslmed.abo7793","article-title":"The past, present, and future of antibiotics.","volume":"14","author":"Cook","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"95","DOI":"10.4103\/jgid.jgid_34_23","article-title":"Doxycycline for multidrug-resistant gram-negative bacterial infection treatment: A scoping review.","volume":"15","author":"De Macedo","year":"2023","journal-title":"J. Glob. Infect. Dis."},{"key":"B11","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.jgar.2024.01.021","article-title":"Evaluation of antibiofilm activity of cefiderocol alone and in combination with imipenem against Pseudomonas aeruginosa.","volume":"37","author":"Ferretti","year":"2024","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"B12","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.diagmicrobio.2018.11.010","article-title":"Minimal inhibitory concentration of omadacycline and doxycycline against bacterial isolates with known tetracycline resistance determinants.","volume":"94","author":"Fluit","year":"2019","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"B13","doi-asserted-by":"publisher","first-page":"180","DOI":"10.37349\/eds.2023.00013","article-title":"Approved antibacterial drugs in the last 10 years: From the bench to the clinic.","volume":"3","author":"Garc\u00eda-Castro","year":"2023","journal-title":"Explor. Drug Sci."},{"key":"B14","doi-asserted-by":"publisher","first-page":"93","DOI":"10.4103\/jgid.jgid_139_23","article-title":"State of the globe: Doxycycline \u2013 an old wine in a new bottle for Gram-negative sepsis.","volume":"15","author":"Ghatak","year":"2023","journal-title":"J. Glob. Infect. Dis."},{"key":"B15","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.diagmicrobio.2019.03.003","article-title":"Reproducibility of broth microdilution MICs for the novel siderophore cephalosporin, cefiderocol, determined using iron-depleted cation-adjusted Mueller\u2013Hinton broth.","volume":"94","author":"Hackel","year":"2019","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"B16","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1099\/jmm.0.001092","article-title":"Same-day antimicrobial susceptibility test using acoustic-enhanced flow cytometry visualized with supervised machine learning.","volume":"69","author":"Inglis","year":"2020","journal-title":"J. Med. Microbiol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"106633","DOI":"10.1016\/j.ijantimicag.2022.106633","article-title":"Clinical data from studies involving novel antibiotics to treat multidrug-resistant Gram-negative bacterial infections.","volume":"60","author":"Kanj","year":"2022","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B18","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3390\/antibiotics10020209","article-title":"Rapid methods for antimicrobial resistance diagnostics.","volume":"10","author":"Kaprou","year":"2021","journal-title":"Antibiotics"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1097\/01.CCM.0000217961.75225.E9","article-title":"Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock.","volume":"34","author":"Kumar","year":"2006","journal-title":"Crit. Care Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"e01443-17","DOI":"10.1128\/AAC.01443-17","article-title":"Vaborbactam: Spectrum of beta-lactamase inhibition and impact of resistance mechanisms on activity in Enterobacteriaceae.","volume":"61","author":"Lomovskaya","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.3390\/microorganisms11051300","article-title":"Current and future flow cytometry applications contributing to antimicrobial resistance control.","volume":"11","author":"Marutescu","year":"2023","journal-title":"Microorganisms"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e0217120","DOI":"10.1128\/AAC.02171-20","article-title":"New perspectives on antimicrobial agents: Cefiderocol.","volume":"65","author":"McCreary","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"B23","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1038\/s41579-024-01054-w","article-title":"ESKAPE pathogens: Antimicrobial resistance, epidemiology, clinical impact and therapeutics.","volume":"22","author":"Miller","year":"2024","journal-title":"Nat. Rev. Microbiol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"104145","DOI":"10.1016\/j.ebiom.2022.104145","article-title":"Same-day confirmation of infection and antimicrobial susceptibility profiling using flow cytometry.","volume":"82","author":"Mulroney","year":"2022","journal-title":"EBioMedicine"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1038\/s41598-017-02009-3","article-title":"Rapid susceptibility profiling of carbapenem-resistant Klebsiella pneumoniae.","volume":"7","author":"Mulroney","year":"2017","journal-title":"Sci. Rep."},{"key":"B26","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","article-title":"Global burden of bacterial antimicrobial resistance in 2019: A systematic analysis.","volume":"399","author":"Murray","year":"2022","journal-title":"Lancet"},{"key":"B27","unstructured":"O\u2019Neill\n              J.\n            \n          \n          Tackling Drug-Resistant Infections Globally: Final Report and Recommendations.\n          \n          2016"},{"key":"B28","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1007\/s40121-020-00344-z","article-title":"An appraisal of the pharmacokinetic and pharmacodynamic properties of meropenem-vaborbactam.","volume":"9","author":"Patrick","year":"2020","journal-title":"Infect. Dis. Ther."},{"key":"B29","doi-asserted-by":"publisher","first-page":"103582","DOI":"10.1016\/j.sjbs.2023.103582","article-title":"Conventional methods and future trends in antimicrobial susceptibility testing.","volume":"30","author":"Salam","year":"2023","journal-title":"Saudi J. Biol. Sci."},{"key":"B30","unstructured":"Breakpoint Tables for Interpretation of MICs and Zone Diameters, version 15.0.\n          \n          2025"},{"key":"B31","unstructured":"Class II Special Controls Guidance Document: Antimicrobial Susceptibility Test (AST) Systems.\n          \n          2009"},{"key":"B32","unstructured":"No Time to Wait: Securing the Future from Drug-Resistant Infections. Report to the Secretary-General of the United Nations.\n          \n          2019"},{"key":"B33","unstructured":"WHO Bacterial Priority Pathogens List.\n          \n          2024"}],"container-title":["Frontiers in Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2026.1817087\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T05:31:49Z","timestamp":1777872709000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2026.1817087\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,4]]},"references-count":33,"alternative-id":["10.3389\/fmicb.2026.1817087"],"URL":"https:\/\/doi.org\/10.3389\/fmicb.2026.1817087","relation":{},"ISSN":["1664-302X"],"issn-type":[{"value":"1664-302X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,4]]},"article-number":"1817087"}}